How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?  

In this case, given that the patient obtained a CR2 to salvage therapy, I would, if they are otherwise eligible, take this patient to transplant given the data presented by Shadman et al., PMID 34570879 which indicates that those with at least a PR from salvage chemotherapy appeared to benefit as mu...

Agree with Dr. @Phillips. In this case, where the patient is in CR, despite early relapse, I would take to auto. I am not sure if she has seen the subgroup analyses from ZUMA-7 and TRANSFORM - I am guessing the patients randomized to SOC who got to a CR with salvage did well. 

ZUMA Trial TRANSFORM Trial Use of CAR-T Cell therapy.Aim for prolonged DFS, result in OS.